Video
The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
"It’s a very comprehensive course, and there’s a hands on component to it as well, where we’ll be able to go into breakout sessions to further discuss some of the cognitive disorders, but also some of the technology that we have to deliver these medicines more effectively."
Held in Washington, DC, the second annual Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress kicks off June 9th and spans 3 days, covering the latest experimental research in movement and related disorders. For advanced practice providers, fellows, and residents, there will be a full-day, CME, pre-congress event that starts the day before.
The event, a joint partnership between the Parkinson & Movement Disorder Alliance (PMD Alliance) and Georgetown Medstar University Hospital, is not just for movement disorder specialists, but other general neurologists, advanced practice providers, psychiatrists, geriatricians, and much more. Those in attendance will be able to earn AMA PRA Category 1 credits, and above all, engage with leaders in the field on topics that have direct impact on clinical settings. Of note, this year’s meeting will have an additional component focusing on cognition, considering recent breakthroughs in the Alzheimer disease and neurodegenerative fields.
Ahead of the meeting, course directors Fernando Pagan, MD, and Yasar Torres-Yaghi, MD, sat down to give an overview of the meeting, and what clinicians should expect. The duo provided perspective on the different educational sessions, the major areas of focus, and why clinicians form all subspecialties can benefit. Furthermore, they gave context on the recent advances in the field and the need to apply research to clinical settings.
2 Commerce Drive
Cranbury, NJ 08512